Welcome to our dedicated page for Quoin Pharmaceuticals SEC filings (Ticker: QNRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading biotech disclosures can feel like deciphering Latin—especially when Quoin Pharmaceuticals’ 10-K packs clinical-trial protocols, dilution tables, and licensing clauses into hundreds of pages. If you have ever asked, “Where can I get Quoin Pharmaceuticals SEC filings explained simply?” or searched for “Quoin Pharmaceuticals quarterly earnings report 10-Q filing,” you know the challenge.
Stock Titan solves it. Our AI parses every submission the instant it lands on EDGAR, transforming raw text into plain-language briefs, trend charts, and red-flag alerts. Want a snapshot of “Quoin Pharmaceuticals insider trading Form 4 transactions” or need “Quoin Pharmaceuticals Form 4 insider transactions real-time” before pivotal study data? One click delivers. Prefer a deeper dive? Our platform links each note in the “Quoin Pharmaceuticals annual report 10-K simplified” to the source paragraph, so you can verify numbers fast. We cover every form—10-Q revenue updates, 8-K trial readouts, S-3 capital raises, even the “Quoin Pharmaceuticals proxy statement executive compensation” sections that detail option grants.
What makes these filings worth tracking? Pipeline milestones, burn-rate disclosures, and “Quoin Pharmaceuticals 8-K material events explained” can shift valuation overnight. Our dashboards highlight upcoming catalysts, compare R&D spend quarter over quarter, and flag any “Quoin Pharmaceuticals earnings report filing analysis” that signals cash runway changes. Whether you’re monitoring “Quoin Pharmaceuticals executive stock transactions Form 4” for confidence signals or simply “understanding Quoin Pharmaceuticals SEC documents with AI,” Stock Titan delivers the clarity researchers, portfolio managers, and retail investors require—without wading through technical jargon.
Quoin Pharmaceuticals (NASDAQ:QNRX), a late clinical-stage specialty pharmaceutical company, announced that the FDA has granted Rare Pediatric Disease (RPD) Designation for their lead asset QRX003, targeting Netherton Syndrome. This significant regulatory milestone was disclosed in an 8-K filing dated June 24, 2025.
The RPD designation for QRX003 represents an important development in the company's rare and orphan disease pipeline, potentially accelerating the path to market for their Netherton Syndrome treatment.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) filed a Form 8-K to announce that its Board has scheduled the 2025 Annual General Meeting of Shareholders ("2025 AGM") for August 21, 2025. Because this date is more than 30 days earlier than the anniversary of the 2024 AGM, previously disclosed shareholder-proposal deadlines are no longer valid.
Revised submission windows:
- Rule 14a-8 proposals: must be received by June 30, 2025 for inclusion in the Company’s proxy materials.
- Universal proxy (Rule 14a-19) director nominations: notice must also be delivered by June 30, 2025, the 10th calendar day after this report’s public announcement.
No financial results, transactions, or strategic changes were disclosed. The filing is primarily a procedural notice affecting shareholders who intend to submit proposals or nominate directors.
FAQ
What is the current stock price of Quoin Pharmaceuticals (QNRX)?
What is the market cap of Quoin Pharmaceuticals (QNRX)?
What is the core mission of Quoin Pharmaceuticals Ltd?
Which therapeutic areas does Quoin Pharmaceuticals focus on?
What makes Quoin's clinical-stage pipeline unique?
How does Quoin Pharmaceuticals differentiate itself in the competitive landscape?
What role do clinical trials play in Quoin's business model?
What are some challenges faced by companies in the rare disease market?
Have strategic partnerships influenced Quoin’s development process?
How does Quoin Pharmaceuticals ensure the quality and reliability of its products?
